Chardan raised the firm’s price target on Krystal Biotech to $208 from $153 and keeps a Buy rating on the shares after the company reported quarterly results. The firm noted that, ahead of upcoming datasets for pipeline candidates, the use of in vivo gene therapy may or may not be feasible in certain genetic and aesthetic dermatological conditions. Chardan added, however, that its new price target is based on a probability-adjusted modeling of key franchises.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates
- Is KRYS a Buy, Before Earnings?
- Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
- Krystal Biotech participates in a conference call with Cantor Fitzgerald
- Krystal Biotech, Virtu, StepStone, Cactus Inc., Tidewater to join S&P 600